Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-kappa B Pathway in Endometrial Cancer
Por:
Yeramian, A, Garcia, V, Bergada, L, Domingo, M, Santacana, M, Valls, J, Martinez-Alonso, M, Carceller, J, Cussac, A, Dolcet, X and Matias-Guiu, X
Publicada:
1 ago 2016
Resumen:
In this study, we first aimed to evaluate the effects in vitro and in vivo, of the Hsp90 inhibitor NVP-AUY922, in endometrial cancer (EC). We also aimed to track nuclear factor kappa B (NF-kappa B) signalling, a key pathway involved in endometrial carcinogenesis and to check whether NVP-AUY922 treatment modulates it both in vitro and in vivo.
I n vitro effects of NVP-AUY922 on EC cell growth and the signalling pathways were assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), clonogenic assays, Western Blot and luciferase assay. NVP-AUY922 effect on Ishikawa (IK) xenograft growth was evaluated in vivo, and NF-kappa B activity was monitored using bioluminescence imaging.
NVP-AUY922 inhibited the growth of three endometrial cell lines tested in vitro. In vivo, NVP-AUY922 reduced tumour growth of 47 % (p = 0.042) compared to control condition. Moreover, the bioluminescence signal of the tumours harbouring IK NF-kappa B-LUC cells was significantly reduced in NVP-AUY922-treated animals compared to untreated ones.
NVP-AUY922 reduced EC tumour growth and NF-kappa B signalling both in vitro and in vivo. As therapeutic resistance of EC remains a challenge for oncologists nowadays, we think that NVP-AUY922 represents a valid alternative to conventional chemotherapy, and we believe that this approach for assessing and tracking the activation of NF-kappa B pathway may be of therapeutic benefit.
Filiaciones:
Yeramian, A:
Univ Lleida, Inst Recerca Biomed Lleida, Dept Pathol & Mol Genet HUAV, Dept Ciencies Med Basiques,IRBLleida, Ave Rovira Roure 80, Lleida 25198, Spain
Garcia, V:
Hosp Arnau Vilanova, Dept Radiat Oncol, Ave Rovira Roure 80, Lleida 25198, Spain
Bergada, L:
Univ Lleida, Inst Recerca Biomed Lleida, Dept Pathol & Mol Genet HUAV, Dept Ciencies Med Basiques,IRBLleida, Ave Rovira Roure 80, Lleida 25198, Spain
Domingo, M:
Univ Lleida, Inst Recerca Biomed Lleida, Dept Pathol & Mol Genet HUAV, Dept Ciencies Med Basiques,IRBLleida, Ave Rovira Roure 80, Lleida 25198, Spain
Santacana, M:
Univ Lleida, Inst Recerca Biomed Lleida, Dept Pathol & Mol Genet HUAV, Dept Ciencies Med Basiques,IRBLleida, Ave Rovira Roure 80, Lleida 25198, Spain
Valls, J:
Univ Lleida, Hosp Univ Arnau de Vilanova, Biostat Unit, IRB Lleida, Ave Rovira Roure 80, Lleida 25198, Spain
Martinez-Alonso, M:
Univ Lleida, Hosp Univ Arnau de Vilanova, Biostat Unit, IRB Lleida, Ave Rovira Roure 80, Lleida 25198, Spain
Carceller, J:
Hosp Arnau Vilanova, Dept Radiat Oncol, Ave Rovira Roure 80, Lleida 25198, Spain
:
Univ Lleida, Hosp Univ Arnau de Vilanova, Dept Oncol, IRB Lleida, Ave Rovira Roure 80, Lleida 25198, Spain
Dolcet, X:
Univ Lleida, Inst Recerca Biomed Lleida, Dept Pathol & Mol Genet HUAV, Dept Ciencies Med Basiques,IRBLleida, Ave Rovira Roure 80, Lleida 25198, Spain
Matias-Guiu, X:
Univ Lleida, Inst Recerca Biomed Lleida, Dept Pathol & Mol Genet HUAV, Dept Ciencies Med Basiques,IRBLleida, Ave Rovira Roure 80, Lleida 25198, Spain
|